The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Keros Therapeutics Inc shares valued at $95,659,436 were sold by ADAR1 Capital Management, LLC on Oct 15 ’25. At $17.75 per share, ADAR1 Capital Management, LLC sold 5,389,264 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, Rovaldi Christopher purchased 85,306 shares, netting a total of over 1,340,157 in proceeds.
Before that, ADAR1 Capital Management, LLC had added 934,258 shares to its account. In a trade valued at $9,464,512, the 10% Owner bought Keros Therapeutics Inc shares for $10.13 each. Upon closing the transaction, the insider’s holdings increased to 934,258 shares, worth approximately $63.65 million.
As published in a research note from BofA Securities on June 10, 2025, Keros Therapeutics Inc [KROS] has been rated down from a Buy to a Neutral and the price target has been revised to $18. Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in late January. As of January 17, 2025, Wedbush has decreased its “an Outperform” rating to a “Neutral” for KROS. Earlier on December 16, 2024, Oppenheimer resumed its rating. Their recommendation was “an Outperform” for KROS stock.
Analyzing KROS Stock Performance
On last trading session, Keros Therapeutics Inc [NASDAQ: KROS] plunged -3.98% to $14.49. The stock’s lowest price that day was $13.93, but it reached a high of $15.03 in the same session. During the last five days, there has been a drop of approximately -9.21%. Over the course of the year, Keros Therapeutics Inc shares have dropped approximately -75.76%.
Is Keros Therapeutics Inc subject to short interest?
Stocks of Keros Therapeutics Inc saw a sharp steep in short interest on 2025-09-30 dropping by -0.63 million shares to 3.87 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 4.5 million shares. A decline of -16.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.92 of the overall float, the days-to-cover ratio (short ratio) decline to 11.92.
Which companies own the most shares of Keros Therapeutics Inc (KROS)?
In terms of Keros Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 105 in the next 12 months, up nearly 595.83% from the previous closing price of $15.09. Analysts anticipate Keros Therapeutics Inc stock to reach 107 by 2025, with the lowest price target being 96. In spite of this, 3 analysts ranked Keros Therapeutics Inc stock as Buy at the end of 2025.